stockrow
Friday 6 November 2026
Export ALLR’s income statement to Excel — free account
Allarity Therapeutics, Inc.
ALLR Healthcare Biotechnology
Allarity Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $320,000.00.
- EPS
- −40.0%
- Free cash flow
- +53.2%
- Total debt
- +3.56%
Quarter to June 2026, against a year earlier
0.96
0.02
−2.04%
Follow ALLR
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 1 | 1 | 0 | 0 | — | — | — | — | — | 0 | — | (7.0%) | 0 | 0 | — | (89.2%) | |
| Gross margin, % | (32.44) | (229.64) | (1,839.97) | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 100.00 | 0.00 | +132.4 pt | ||||||
| EBT | (2) | (4) | (3) | (2) | (6) | (27) | (18) | (12) | (25) | (11) | (12) | +24.9% | ||||||
| EBT margin, % | (245.85) | (521.65) | (989.01) | (15,814.17) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (3,509.69) | 0.00 | (3,263.8) pt | ||||||
| Net income | (2) | 0 | (2) | (2) | (7) | (27) | (16) | (12) | (25) | (11) | (12) | +24.3% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 1.05 | 1.34 | 0.39 | 0.28 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | (34.8%) | |||||
| Earnings | — | — | — | (33.98) | (2.03) | (4.19) | (1,856,336.00) | (6,031.31) | (15.65) | (0.78) | (0.78) | (46.7%) | ||||||
| Cash flow | (2.01) | (2.17) | (4.96) | (24.00) | (2.22) | (2.34) | 0.00 | (3,765.14) | (10.80) | (1.03) | (0.86) | (7.1%) | ||||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.19) | 0.00 | (0.02) | n/m | ||||||
| Free cash flow | (2.01) | (2.17) | (4.96) | (24.00) | (2.22) | (2.34) | 0.00 | (3,765.14) | (10.98) | (1.03) | (0.88) | (7.1%) | ||||||
| Book value | 2.74 | 0.65 | 27.46 | 42.93 | 7.49 | 2.85 | 0.00 | (812.70) | 7.35 | 0.68 | 0.22 | (14.3%) | ||||||
| Shares, m | 1 | 1 | 1 | 0 | 3 | 6 | 0 | 0 | 2 | 14 | 15 | +42.6% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | 0.00 | 0.00 | 0.0 | |||||
| P/S | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | 0.00 | 0.00 | 0.0 | ||||||
| P/B | 2,305,433.40 | 2,305,433.40 | 2,305,433.40 | 2,305,433.40 | — | — | — | — | — | 1.58 | 4.32 | 1,844,347.0 | ||||||
| EV/Sales | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | 0.00 | 0.00 | 0.0 | ||||||
| EV/FCF | (5,257,685.33) | (5,257,685.33) | (5,257,685.33) | (5,257,685.33) | — | — | — | — | — | (0.23) | 0.65 | (4,206,148.3) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (1) | (1) | (4) | (1) | (7) | (15) | (17) | (13) | (17) | (15) | (14) | +32.5% | |||||
| Capex | 0 | — | 0 | 0 | 0 | — | 0 | — | 0 | 0 | 0 | (1.9%) | ||||||
| Free cash flow | (1) | (1) | (4) | (1) | (7) | (15) | (17) | (13) | (18) | (15) | (14) | +32.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 1 | 0 | (3) | 0 | (4) | 1 | (6) | (12) | 12 | 9 | 3 | +25.5% | |||||
| Net debt | (1) | (1) | 3 | 0 | 2 | (19) | 2 | 1 | (18) | (13) | (26) | +37.0% | ||||||
| Shareholders’ equity | 2 | 0 | 24 | 2 | 24 | 18 | 0 | (3) | 12 | 10 | 4 | +22.3% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (71.91) | (412.00) | (11.35) | (7.41) | (35.88) | (64.18) | (65.60) | (154.63) | (145.77) | (54.91) | (46.26) | +17.0 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | (19.73) | 0.00 | (1,358.95) | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (158.64) | (479.08) | (19.21) | (12.09) | (50.05) | (125.13) | (233.39) | 886.50 | (687.46) | (103.80) | (157.09) | +54.8 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 13 | 9 | 6 | 7 | 8 | — | (11.4%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Mar 2026 · fundamentals updated 26 Oct 2026
Allarity Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| JSPR Jasper Therapeutics, Inc. | $15.6M | — (loss-making) | — | — | n/m | +55.74% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NCEL NewcelX Ltd. | $15.6M | — (loss-making) | — | — | n/m | −87.71% (below 0%: shrinking) | 0.00% | — | Compare |
| ALLR Allarity Therapeutics, Inc. | $15.5M | — (loss-making) | — (loss-making) | — | n/m | +53.22% (above 0%: growing) | 100.00% | 0.00% | |
| VAXX Vaxxinity, Inc. | $15.5M | — (loss-making) | — (loss-making) | −100.23% (below 0%: shrinking) | n/m | +17.00% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ABOS Acumen Pharmaceuticals, Inc. | $15.5M | — (loss-making) | — | — | n/m | +12.58% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CTXR Citius Pharmaceuticals, Inc. | $15.3M | — (loss-making) | — | — | n/m | −60.50% (below 0%: shrinking) | 67.07% | (785.39%) | Compare |
| PLUR Pluri Inc. | $15.0M | — (loss-making) | — (loss-making) | −15.83% (below 0%: shrinking) | n/m | +25.03% (above 0%: growing) | 58.51% | (1,655.52%) | Compare |
| NEUP Neuphoria Therapeutics Inc. | $15.0M | — (loss-making) | — (loss-making) | −107.32% (below 0%: shrinking) | n/m | +133.86% (above 0%: growing) | 100.00% | 0.00% | Compare |
| MRKR MARKER THERAPEUTICS, INC. | $14.9M | — (loss-making) | — (loss-making) | −51.00% (below 0%: shrinking) | n/m | −97.84% (below 0%: shrinking) | 209.68% | 0.00% | Compare |
| Median of peers | $15.4M | — | — | −75.61% | — | +14.79% | 29.26% | 0.00% |
Pay and ownership Proxy statement filed 30 April 2026
Ownership
Directors and executive officers, together
less than 1%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement